{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T22:34:01Z","timestamp":1793745241426,"version":"4.6.1"},"reference-count":29,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2023,8,17]],"date-time":"2023-08-17T00:00:00Z","timestamp":1692230400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2023,8,17]],"date-time":"2023-08-17T00:00:00Z","timestamp":1692230400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/100000054","name":"U.S. Department of Health & Human Services | NIH | National Cancer Institute","doi-asserted-by":"publisher","award":["P01 CA244118"],"award-info":[{"award-number":["P01 CA244118"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"U.S. Department of Health & Human Services | NIH | National Cancer Institute","doi-asserted-by":"publisher","award":["R35 CA197633"],"award-info":[{"award-number":["R35 CA197633"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"U.S. Department of Health & Human Services | NIH | National Cancer Institute","doi-asserted-by":"publisher","award":["LS1616_R01LDRGAPP01"],"award-info":[{"award-number":["LS1616_R01LDRGAPP01"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"U.S. Department of Health & Human Services | NIH | National Cancer Institute","doi-asserted-by":"publisher","award":["U10CA180888"],"award-info":[{"award-number":["U10CA180888"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"U.S. Department of Health & Human Services | NIH | National Cancer Institute","doi-asserted-by":"publisher","award":["U10CA180821"],"award-info":[{"award-number":["U10CA180821"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"U.S. Department of Health & Human Services | NIH | National Cancer Institute","doi-asserted-by":"publisher","award":["U10CA18068"],"award-info":[{"award-number":["U10CA18068"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009730","name":"EIF | Stand Up To Cancer","doi-asserted-by":"publisher","award":["CT06-17"],"award-info":[{"award-number":["CT06-17"]}],"id":[{"id":"10.13039\/100009730","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Med"],"published-print":{"date-parts":[[2023,9]]},"DOI":"10.1038\/s41591-023-02498-y","type":"journal-article","created":{"date-parts":[[2023,8,17]],"date-time":"2023-08-17T12:01:34Z","timestamp":1692273694000},"page":"2278-2285","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":190,"title":["Ipilimumab with or without nivolumab in PD-1 or PD-L1 blockade refractory metastatic melanoma: a randomized phase 2 trial"],"prefix":"10.1038","volume":"29","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6842-2563","authenticated-orcid":false,"given":"Ari","family":"VanderWalde","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shay L.","family":"Bellasea","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kari L.","family":"Kendra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nikhil I.","family":"Khushalani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6491-4432","authenticated-orcid":false,"given":"Katie M.","family":"Campbell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2563-2042","authenticated-orcid":false,"given":"Philip O.","family":"Scumpia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lawrence F.","family":"Kuklinski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frances","family":"Collichio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey A.","family":"Sosman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4448-9755","authenticated-orcid":false,"given":"Alexandra","family":"Ikeguchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adrienne I.","family":"Victor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thach-Giao","family":"Truong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2374-3320","authenticated-orcid":false,"given":"Bartosz","family":"Chmielowski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David C.","family":"Portnoy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuanbin","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5248-4356","authenticated-orcid":false,"given":"Kim","family":"Margolin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charles","family":"Bane","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Constantin A.","family":"Dasanu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6390-773X","authenticated-orcid":false,"given":"Douglas B.","family":"Johnson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zeynep","family":"Eroglu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sunandana","family":"Chandra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Egmidio","family":"Medina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cynthia R.","family":"Gonzalez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ignacio","family":"Baselga-Carretero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Agustin","family":"Vega-Crespo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ivan Perez","family":"Garcilazo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0044-9719","authenticated-orcid":false,"given":"Elad","family":"Sharon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Siwen","family":"Hu-Lieskovan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1339-1517","authenticated-orcid":false,"given":"Sapna P.","family":"Patel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenneth F.","family":"Grossmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James","family":"Moon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael C.","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3669-8458","authenticated-orcid":false,"given":"Antoni","family":"Ribas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,8,17]]},"reference":[{"key":"2498_CR1","doi-asserted-by":"publisher","first-page":"320","DOI":"10.1056\/NEJMoa1412082","volume":"372","author":"C Robert","year":"2015","unstructured":"Robert, C. et al. Nivolumab in previously untreated melanoma without BRAF mutation. N. Engl. J. Med. 372, 320\u2013330 (2015).","journal-title":"N. Engl. J. Med."},{"key":"2498_CR2","doi-asserted-by":"publisher","first-page":"2521","DOI":"10.1056\/NEJMoa1503093","volume":"372","author":"C Robert","year":"2015","unstructured":"Robert, C. et al. Pembrolizumab versus ipilimumab in advanced melanoma. N. Engl. J. Med. 372, 2521\u20132532 (2015).","journal-title":"N. Engl. J. Med."},{"key":"2498_CR3","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1056\/NEJMoa1504030","volume":"373","author":"J Larkin","year":"2015","unstructured":"Larkin, J. et al. Combined nivolumab and ipilimumab or monotherapy in untreated melanoma. N. Engl. J. Med. 373, 23\u201334 (2015).","journal-title":"N. Engl. J. Med."},{"key":"2498_CR4","doi-asserted-by":"publisher","first-page":"1600","DOI":"10.1001\/jama.2016.4059","volume":"315","author":"A Ribas","year":"2016","unstructured":"Ribas, A. et al. Association of pembrolizumab with tumor response and survival among patients with advanced melanoma. JAMA 315, 1600\u20131609 (2016).","journal-title":"JAMA"},{"key":"2498_CR5","doi-asserted-by":"publisher","first-page":"568","DOI":"10.1038\/nature13954","volume":"515","author":"PC Tumeh","year":"2014","unstructured":"Tumeh, P. C. et al. PD-1 blockade induces responses by inhibiting adaptive immune resistance. Nature 515, 568\u2013571 (2014).","journal-title":"Nature"},{"key":"2498_CR6","doi-asserted-by":"publisher","first-page":"1350","DOI":"10.1126\/science.aar4060","volume":"359","author":"A Ribas","year":"2018","unstructured":"Ribas, A. & Wolchok, J. D. Cancer immunotherapy using checkpoint blockade. Science 359, 1350\u20131355 (2018).","journal-title":"Science"},{"key":"2498_CR7","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1126\/science.aaa8172","volume":"348","author":"P Sharma","year":"2015","unstructured":"Sharma, P. & Allison, J. P. The future of immune checkpoint therapy. Science 348, 56\u201361 (2015).","journal-title":"Science"},{"key":"2498_CR8","doi-asserted-by":"publisher","first-page":"1490","DOI":"10.1056\/NEJMp1510079","volume":"373","author":"A Ribas","year":"2015","unstructured":"Ribas, A. Releasing the brakes on cancer immunotherapy. N. Engl. J. Med. 373, 1490\u20131492 (2015).","journal-title":"N. Engl. J. Med."},{"key":"2498_CR9","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1016\/j.cell.2015.03.030","volume":"161","author":"P Sharma","year":"2015","unstructured":"Sharma, P. & Allison, J. P. Immune checkpoint targeting in cancer therapy: toward combination strategies with curative potential. Cell 161, 205\u2013214 (2015).","journal-title":"Cell"},{"key":"2498_CR10","doi-asserted-by":"publisher","first-page":"1120","DOI":"10.1016\/j.cell.2017.07.024","volume":"170","author":"SC Wei","year":"2017","unstructured":"Wei, S. C. et al. Distinct cellular mechanisms underlie anti-CTLA-4 and anti-PD-1 checkpoint blockade. Cell 170, 1120\u20131133 (2017).","journal-title":"Cell"},{"key":"2498_CR11","doi-asserted-by":"publisher","first-page":"22699","DOI":"10.1073\/pnas.1821218116","volume":"116","author":"SC Wei","year":"2019","unstructured":"Wei, S. C. et al. Combination anti-CTLA-4 plus anti-PD-1 checkpoint blockade utilizes cellular mechanisms partially distinct from monotherapies. Proc. Natl Acad. Sci. USA 116, 22699\u201322709 (2019).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"2498_CR12","doi-asserted-by":"publisher","first-page":"340","DOI":"10.2967\/jnumed.109.070946","volume":"51","author":"A Ribas","year":"2010","unstructured":"Ribas, A. et al. Imaging of CTLA4 blockade-induced cell replication with 18F-FLT PET in patients with advanced melanoma treated with tremelimumab. J. Nucl. Med. 51, 340\u2013346 (2010).","journal-title":"J. Nucl. Med."},{"key":"2498_CR13","doi-asserted-by":"publisher","first-page":"238ra270","DOI":"10.1126\/scitranslmed.3008211","volume":"6","author":"E Cha","year":"2014","unstructured":"Cha, E. et al. Improved survival with T cell clonotype stability after anti-CTLA-4 treatment in cancer patients. Sci. Transl. Med. 6, 238ra270 (2014).","journal-title":"Sci. Transl. Med."},{"key":"2498_CR14","doi-asserted-by":"publisher","first-page":"e29244","DOI":"10.4161\/onci.29244","volume":"3","author":"L Robert","year":"2014","unstructured":"Robert, L. et al. Distinct immunological mechanisms of CTLA-4 and PD-1 blockade revealed by analyzing TCR usage in blood lymphocytes. Oncoimmunology 3, e29244 (2014).","journal-title":"Oncoimmunology"},{"key":"2498_CR15","doi-asserted-by":"publisher","first-page":"2424","DOI":"10.1158\/1078-0432.CCR-13-2648","volume":"20","author":"L Robert","year":"2014","unstructured":"Robert, L. et al. CTLA4 blockade broadens the peripheral T-cell receptor repertoire. Clin. Cancer Res. 20, 2424\u20132432 (2014).","journal-title":"Clin. Cancer Res."},{"key":"2498_CR16","doi-asserted-by":"publisher","first-page":"4101","DOI":"10.1158\/1078-0432.CCR-11-0407","volume":"17","author":"RR Huang","year":"2011","unstructured":"Huang, R. R. et al. CTLA4 blockade induces frequent tumor infiltration by activated lymphocytes regardless of clinical responses in Humans. Clin. Cancer Res. 17, 4101\u20134109 (2011).","journal-title":"Clin. Cancer Res."},{"key":"2498_CR17","doi-asserted-by":"publisher","first-page":"5064","DOI":"10.1158\/1078-0432.CCR-13-3271","volume":"20","author":"JM Taube","year":"2014","unstructured":"Taube, J. M. et al. Association of PD-1, PD-1 ligands, and other features of the tumor immune microenvironment with response to anti-PD-1 therapy.Clin. Cancer Res. 20, 5064\u20135074 (2014).","journal-title":"Clin. Cancer Res."},{"key":"2498_CR18","doi-asserted-by":"publisher","first-page":"836","DOI":"10.1016\/S1470-2045(21)00097-8","volume":"22","author":"I Pires da Silva","year":"2021","unstructured":"Pires da Silva, I. et al. Ipilimumab alone or ipilimumab plus anti-PD-1 therapy in patients with metastatic melanoma resistant to anti-PD-(L)1 monotherapy: a multicentre, retrospective, cohort study. Lancet Oncol. 22, 836\u2013847 (2021).","journal-title":"Lancet Oncol."},{"key":"2498_CR19","doi-asserted-by":"publisher","first-page":"2647","DOI":"10.1200\/JCO.21.00079","volume":"39","author":"DJ Olson","year":"2021","unstructured":"Olson, D. J. et al. Pembrolizumab plus ipilimumab following anti-PD-1\/L1 failure in melanoma. J. Clin. Oncol. 39, 2647\u20132655 (2021).","journal-title":"J. Clin. Oncol."},{"key":"2498_CR20","doi-asserted-by":"publisher","first-page":"e003853","DOI":"10.1136\/jitc-2021-003853","volume":"10","author":"CF Friedman","year":"2022","unstructured":"Friedman, C. F. et al. Ipilimumab alone or in combination with nivolumab in patients with advanced melanoma who have progressed or relapsed on PD-1 blockade: clinical outcomes and translational biomarker analyses. J. Immunother. Cancer 10, e003853 (2022).","journal-title":"J. Immunother. Cancer"},{"key":"2498_CR21","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1016\/j.ejca.2016.03.081","volume":"62","author":"LH Schwartz","year":"2016","unstructured":"Schwartz, L. H. et al. RECIST 1.1\u2014update and clarification: from the RECIST committee. Eur. J. Cancer 62, 132\u2013137 (2016).","journal-title":"Eur. J. Cancer"},{"key":"2498_CR22","doi-asserted-by":"publisher","first-page":"1861","DOI":"10.1093\/annonc\/mdy226","volume":"29","author":"MT Tetzlaff","year":"2018","unstructured":"Tetzlaff, M. T. et al. Pathological assessment of resection specimens after neoadjuvant therapy for metastatic melanoma. Ann. Oncol. 29, 1861\u20131868 (2018).","journal-title":"Ann. Oncol."},{"key":"2498_CR23","doi-asserted-by":"publisher","first-page":"1535","DOI":"10.1056\/NEJMoa1910836","volume":"381","author":"J Larkin","year":"2019","unstructured":"Larkin, J. et al. Five-year survival with combined nivolumab and ipilimumab in advanced melanoma. N. Engl. J. Med. 381, 1535\u20131546 (2019).","journal-title":"N. Engl. J. Med."},{"key":"2498_CR24","doi-asserted-by":"publisher","first-page":"e000398","DOI":"10.1136\/jitc-2019-000398","volume":"8","author":"HM Kluger","year":"2020","unstructured":"Kluger, H. M. et al. Defining tumor resistance to PD-1 pathway blockade: recommendations from the first meeting of the SITC Immunotherapy Resistance Taskforce. J. Immunother. Cancer 8, e000398 (2020).","journal-title":"J. Immunother. Cancer"},{"key":"2498_CR25","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1056\/NEJMoa2109970","volume":"386","author":"HA Tawbi","year":"2022","unstructured":"Tawbi, H. A. et al. Relatlimab and nivolumab versus nivolumab in untreated advanced melanoma. N. Engl. J. Med. 386, 24\u201334 (2022).","journal-title":"N. Engl. J. Med."},{"key":"2498_CR26","doi-asserted-by":"publisher","first-page":"186","DOI":"10.1200\/JCO.22.01763","volume":"41","author":"MB Atkins","year":"2023","unstructured":"Atkins, M. B. et al. Combination dabrafenib and trametinib versus combination nivolumab and ipilimumab for patients with advanced BRAF-mutant melanoma: the DREAMseq Trial-ECOG-ACRIN EA6134. J. Clin. Oncol. 41, 186\u2013197 (2023).","journal-title":"J. Clin. Oncol."},{"key":"2498_CR27","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1038\/nrclinonc.2017.43","volume":"14","author":"JJ Luke","year":"2017","unstructured":"Luke, J. J., Flaherty, K. T., Ribas, A. & Long, G. V. Targeted agents and immunotherapies: optimizing outcomes in melanoma. Nat. Rev. Clin. Oncol. 14, 463\u2013482 (2017).","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"2498_CR28","doi-asserted-by":"publisher","first-page":"2113","DOI":"10.1056\/NEJMoa2210233","volume":"387","author":"MW Rohaan","year":"2022","unstructured":"Rohaan, M. W. et al. Tumor-infiltrating lymphocyte therapy or ipilimumab in advanced melanoma. N. Engl. J. Med. 387, 2113\u20132125 (2022).","journal-title":"N. Engl. J. Med."},{"key":"2498_CR29","doi-asserted-by":"publisher","first-page":"707","DOI":"10.1016\/j.cell.2017.01.017","volume":"168","author":"P Sharma","year":"2017","unstructured":"Sharma, P., Hu-Lieskovan, S., Wargo, J. A. & Ribas, A. Primary, adaptive, and acquired resistance to cancer immunotherapy. Cell 168, 707\u2013723 (2017).","journal-title":"Cell"}],"container-title":["Nature Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41591-023-02498-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41591-023-02498-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41591-023-02498-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,10]],"date-time":"2026-07-10T07:17:44Z","timestamp":1783667864000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41591-023-02498-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,8,17]]},"references-count":29,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2023,9]]}},"alternative-id":["2498"],"URL":"https:\/\/doi.org\/10.1038\/s41591-023-02498-y","relation":{},"ISSN":["1078-8956","1546-170X"],"issn-type":[{"value":"1078-8956","type":"print"},{"value":"1546-170X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,8,17]]},"assertion":[{"value":"23 February 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 July 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 August 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A.V. declares employment by Caris Life Sciences and consults with the George Clinical, West Clinic; he sits on the advisory boards and steering committees of Bristol Myers Squibb, Genentech and Mirati Therapeutics. He has received research funding from SWOG, Stand Up 2 Cancer, Bristol Myers Squibb and American Association for Cancer Research. K.L.K. reports clinical trial funding through the institution from Merck. N.I.K. sits on the advisory board for Bristol Myers Squibb, Regeneron, Merck, Iovance Biotherapeutics, Genzyme, Novartis, Nektar, Castle Biosciences, Instil Bio and the National Comprehensive Cancer Network (via Pfizer); he is a member of the study steering committees of Bristol Myers Squibb, Nektar, Regeneron and Replimune; he is a member of the data safety monitoring boards of Astra-Zeneca and Incyte; he holds common stock stock in Bellicum Pharmaceuticals, Asensus Surgical and Amarin Corporation; and he has received research funding (to the institute) from Bristol Myers Squibb, Merck, Novartis, GSK, HUYA Bioscience International, Amgen, Regeneron, Celgene, Replimmune and Modulation Therapeutics. K.M.C. reports being a shareholder in Geneoscopy and has received consulting fees from Geneoscopy, PACT Pharma, Tango Therapeutics, Flagship Labs 81 and the Rare Cancer Research Foundation. P.S. received research funding, consulted for and served on the advisory board for Castle Biosciences. F.C. reports that his institution receives research funding for clinical trials. A portion of that funding comes from trials sponsored by Amgen and Replimune and helps cover her salary. J.A.S. reports consultation for Apixagen Consultation, Iovance and Necktor and up-to-date royalties. A.I. discloses research funding to her institution from Checkmate Pharmaceuticals, Dynavax Technologies, GSK\/S. Cannon, Immunocore, Merck and Neon Therapeutics\/S. Cannon. A.I.V. had an investigator-initiated study supported by Bristol Myers Squibb, but it closed 2 years ago and understands that it does not qualify as a competing interest. T.-G.T. reports institutional funding from Bristol Myears Squibb, Merck, Roche, Pfizer, Novartis, Regeneron and Astra-Zeneca. B.C. reports clinical trial support paid to his institution from SWOG, Bristol Myers Squibb, Macrogenics, Merck, Karyopharm, Infinity, Advenchen, Idera, Xencor, Compugen, Iovance, PACT Pharma, RAPT Therapeutics, Immunocore, IDEAYA, Ascentage, Novartis, Atreca, Replimmune, Instil Bio, Adagene, TriSalus and Xilio; he reports payment for lectures for Sanofi Genzyme and sits on the advisory boards of Instil Bio, Nektar, Delcath, Novartis, Genentech, IDEAYA, OncoSec, Iovance and Deciphera. Y.C. reports research funding from BMS RELATIVITY-098 to his institution, personal financial interest in Bristol Myers Squibb as speaker on melanoma and is a member of the advisory board; he has spoken about melanoma on behalf of Pfizer. D.B.J. has served on the advisory boards or as a consultant for Bristol Myears Squibb, Catalyst Biopharma, Iovance, Jansen, Mallinckrodt, Merck, Mosaic ImmunoEngineering, Novartis, Oncosec, Pfizer, Targovax and Teiko, and has received research funding from Bristol Myears Squibb and Incyte. Z.E. reports serving on the advisory boards of Array BioPharma, Pfizer, OncoSec, Regeneron, Genentech, Novartis and Natera; she has received research funding from Novartis, Pfizer and Boehringer Ingelheim. S.C. reports serving on the advisory boards of Bristol Myers Squibb, Novartis, Pfizer and Regeneron. S.H-L. reports consulting for Amgen, Genmab, Xencor, Regeneron, Nektar, Astellas, Bristol Myers Squibb and Merck; she reports support from Amgen and Merck, and has undertaken contracted research for Pfizer, Plexxikon, Genentech, Neon Therapeutics, Nektar, Astellas, F Star, Xencor, Merck, Vedanta, Kite Pharma, Boehringer Ingelheim, OncoC4, Dragonfly, Bristol Myers Squibb and BioAlta. S.P.P. reports the following relevant competing interests: clinical trial support to her institution from Bristol Myers Squibb; advisory board membership of Cardinal Health, Castle Biosciences and Delcath; serving as a consultant for Foghorn Therapeutics (clinical trial support to her institution); providing clinical trial support for Ideaya (via her institution); sitting on the data safety monitoring board of Immunocore; sitting on the advisory board of Immatics; providing clinical trial support via her institution to InxMed, Lyvgen Biopharma and Novartis; serving as consultant on the advisory board of Pfizer; providing clinical trial support to Provectus Biopharmaceuticals; providing clinical trial support via her institution to Reata Pharmaceuticals and sitting on the data safety monitoring board; she has sat on the advisory board of Replimmune and the scientific advisory board of TriSalus Life Sciences; and she has provided clinical trial support (via her institution) to Seagen and Syntrix Bio, and has consulted for Advance Knowledge in Healthcare. K.F.G. is an employee and stockholder of Merck Sharp & Dohme, a subsidiary of Merck & Co. A.R. has received honoraria from consulting with Amgen, Bristol Myers Squibb and Merck; is or has been a member of the scientific advisory board and holds stock in Advaxis, Appia, Apricity, Arcus, Compugen, CytomX, Highlight, ImaginAb, ImmPact, ImmuneSensor, Inspirna, Isoplexis, Kite-Gilead, Lutris, MapKure, Merus, PACT, Pluto, RAPT Therapeutics, Synthekine and Tango; and has received research funding from Agilent and from Bristol Myers Squibb through SU2C, and patent royalties from Arsenal Bio. J.M., L.F.K., D.C.P., K.M., C.L.B., C.A.D., E.M., C.R.G., I.B.C., A.V-C., I.P.G., E.S., S.L.B. and M.C.W. declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}